A Peptide-Based Nanocarrier for an Enhanced Delivery and Targeting of Flurbiprofen into the Brain for the Treatment of Alzheimer’s Disease: An In Vitro Study

A Peptide-Based Nanocarrier for an Enhanced Delivery and Targeting of Flurbiprofen into the Brain for the Treatment of Alzheimer’s Disease: An In Vitro Study

Alzheimer’s disease (AD) is an age-related disease caused by abnormal accumulation of amyloid-β in the brain leading to progressive tissue degeneration. Flurbiprofen (FP), a drug used to mitigate the disease progression, has low efficacy due to its limited permeability across the blood–brain barrier...

Full description

Bibliographic Details
Main Authors: Shafq Al-azzawi, Dhafir Masheta, Anna Guildford, Gary Phillips, Matteo Santin
Format: Article
Language:English
Published: MDPI AG 2020-08-01
Series:Nanomaterials
Subjects:
Alzheimer’s disease
neurodegenerative diseases
blood–brain barrier
ApoE-peptide
drug delivery system
flurbiprofen
Online Access:https://www.mdpi.com/2079-4991/10/8/1590

Similar Items

Similar Items